

WWW.TRANSVAC.ORG



TRANSVAC-DS

TOWARDS A SUSTAINABLE EUROPEAN VACCINE INFRASTRUCTURE

Vaccine development is our best bet to tackle epidemic outbreaks and pandemics, but it's time consuming and complex. Despite recent mobilization, researchers still have limited access to capabilities to transfer their discovery into clinical development and commercialization.

DRIVING VACCINE INNOVATION IN EUROPE FOR 10+ YEARS



**~70 TECHNICAL SERVICES
ACROSS THE R&D PIPELINE**

**>60 VACCINE
DEVELOPMENT PROJECTS**

**OPERATES IN ~10 EUROPEAN
COUNTRIES**

TRANSVAC is a pan-European Research Infrastructure project dedicated to accelerate vaccine development. It brings together leading European groups with longstanding experience in the field of vaccines.

TRANSVAC is uniquely positioned to set up a Bio-Holding to transform European vaccine space

**PAST:
BUILDING THE CORE
2009-2017**

Core infrastructure with a limited number of partners and services for human prophylactic vaccines

**TODAY:
EXPANSION
2017-2021**

Expanded infrastructure to 25+ partners and broadened services and support to veterinary and human vaccines (prophylactic and therapeutic)

**FUTURE:
HYBRID BIO-HOLDING
2021+**

Create a Bio-Holding dedicated to business building to solidify impact at scale

How to get involved?



TRANSVAC will establish a diverse portfolio of vaccine projects where one can invest.



TRANSVAC is well equipped to support the acceleration of successful vaccine businesses

TRACK RECORD OF VALUE CHAIN AND TRANSVERSAL SERVICES*

- Assays & Models
- Technology
- Adjuvants
- Regulatory and Clinical expertise
- Training
- Network

*TRANSVAC & TRANSVAC2 EU-funded projects

TRANSVAC'S PATH FORWARD IS TO FOCUS ON BUSINESS BUILDING

- Active investor scouting and outreach support
- Evaluating commercial viability
- Portfolio Management
- Funding
- Business Building and Coaching

TRANSVAC will deliver commercial impact at scale as a vaccine business building entity

WHAT WOULD IT TAKE US TO GET THERE?

Receive investments



Expand service offer



Continue building out portfolio of vaccine candidates



1st performance evaluation milestone



YEAR 1

YEAR 2



Briefing pack for the first candidates



Activate management team with strategic & commercial expertise



Onboard & start securing deals for additional vaccine candidates



First subsidiaries confirmed

CONTACT US

European Vaccine Initiative (EVI)

✉ transvacinfo@euvaccine.eu

☎ 0049 17660863372

CONNECT

www.transvac.org/transvac-ds



European Vaccine Initiative



@EuropeVaccine

NETWORK
25
PARTNERS

FUNDER
EUROPEAN
UNION

TIMELINE
1 JUNE 2020
- 31 MAY 2022

COORDINATOR
EUROPEAN VACCINE
INITIATIVE



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 951668.